CrossRef The efficacy and safety of novel antidiabetic agents in polycystic ovary syndrome: a network meta-analysis Junjie Lin, Rongtao Yang, Jiacheng Zhuang, Wenbo Zhang, Qiang Tong, Jiahui Liu, Ye Kang, Yuan Yuan Journal of Ovarian Research.2026;[Epub] CrossRef Hypothalamus-liver talks: whispers in the language of metabolism Vitor Ferreira, Iara Fernndez-Gonzlez, Jane Jose Vattathara, Amanda Rodrguez-Daz, Paola Fernndez-Sanmartn, Carlos Diguez Reviews in Endocrine and Metabolic Disorders.2026
Although combined therapy is still not common practice because of the relatively recent regulatory approval, these studies highlight the potential of dual GLP-1 RA + SGLT2i therapy to synergistically reduce cardiovascular disease and decelerate renal decompensation [75]
Indications & Research Applications Published research has examined Retatrutide in the context of obesity and type 2 diabetes, with studies reporting effects on body weight, glycemic measures, and metabolic biomarkers [3]
Glucagon-like peptide-1 (GLP-1) receptor agonist drugs like Ozempic and Mounjaro can help treat obesity, type 2 diabetes, and related health conditions